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Atrial ﬁbrillation (AF) has been gaining much attention as one of the major causes of
cerebral infarction. It is imperative to establish antithrombotic treatment for AF
patients. Thus far, guidelines for antithrombotic treatment in the management of AF
patients, including the veriﬁcation of the efﬁcacy of direct thrombin and factor Xa
inhibitors, have been published from the United States, Europe, Canada, and Japan.
When we look at the Asia-Paciﬁc region, antithrombotic treatment has not yet been
deﬁned, and no such guidelines have been published in this regard. The Asia-Paciﬁc
Heart Rhythm Society (APHRS) conducted a Web-based survey between June and
August 2011, to elucidate the current status of antithrombotic treatment in 9 countries.
A total of 363 cardiologists in 9 countries examined 300 patients with cardiovas-
cular disease per month on an average; of these patients, 37 (12%) had nonvalvular AF
(NVAF; 6.5% in India to 16.9% in Australia).
The survey revealed that NVAF patients were not always administered appropriate
antithrombotic treatment. These data give us a foothold for the next step, i.e., the
formulation, of the APHRS practice guidelines.
& 2012 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.rt Rhythm Society. Publish
ity of Health and
o, Japan.1. Background
Along with the aging of the population, the prevalence
of atrial ﬁbrillation (AF) has been rapidly increasing [1].ed by Elsevier B.V. All rights reserved.
S. Ogawa et al. / Journal of Arrhythmia 28 (2012) 41–5542AF has been gaining much attention as one of the major
causes of cerebral infarction [2], which highlights the
importance of the establishment of antithrombotic treat-
ment for AF patients. Thus far, guidelines for antithrom-
botic treatment have been published from Europe, the
United States [3], Canada [4], and Japan (JPN) [5]. The
European Society of Cardiology has recently published
updated guidelines [6], including data on the veriﬁcation
of the effectiveness of direct thrombin and factor Xa
inhibitors. However, no such guidelines have been estab-
lished for the Asia-Paciﬁc region, and optimal antithrom-
botic treatment for AF patients from this region has not
yet been deﬁned.
In 2010, the Asia-Paciﬁc Heart Rhythm Society (APHRS)
founded the ‘‘Practice Guideline Subcommittee’’ (Chairman:
Satoshi Ogawa), with the main purpose of formulating its
own guidelines. As part of the ﬁrst step in its preparation,
the subcommittee conducted a Web-based survey to under-
stand the current practices in 9 Asia-Paciﬁc countries for
preventing stroke and systemic thromboembolism in non-
valvular AF (NVAF) patients.
2. Methods
A Web-based survey was conducted among cardiolo-
gists in 9 Asia-Paciﬁc countries. In 6 countries, the cardiol-
ogists on the registration lists prepared by the survey
companies were sequentially asked to answer the ques-
tionnaire. Physicians meeting the following criteria were
qualiﬁed to participate in the survey: those prescribing
antithrombotic agents for NVAF patients, those who exam-
ined a minimum of 50 patients with cardiovascular dis-
eases per month, those with clinical experience of 5–35
years, and those spending 50% of professional time in
patient care. When 50 eligible responses were obtained,
the survey was considered complete. In the remaining 3
countries (New Zealand, NZL; Singapore, SGP; and Hong
Kong, HKG), there were no registration lists, and despiteFig. 1. Physicians’ backgroattempts by members of the subcommittee in each of
these countries to seek the cooperation of the other
members of the cardiovascular societies in their respective
countries, less than 50 responses were obtained from these
countries. The method of recruitment of subjects and the
number of subjects varied among countries; therefore, the
results are shown only for reference.
The number of beds in the medical facilities at which
the physicians worked was variable, ranging from 9 beds
or less in smaller clinics to 500 beds or more in hospitals.
The results revealed that many physicians worked in
small-scale facilities in India (IND). In China (CHN),
Korea (KOR), Taiwan (TWN), and SGP, the majority of
physicians worked in hospitals with 500 or more beds. This
difference may have had some inﬂuence on the survey
results.
The physicians surveyed the examined 300 patients
with cardiovascular disease per month on an average, and
of these, 37 (12%) had NVAF (Fig. 1). There were no
signiﬁcant differences among countries (5/76 patients or
6.5% in IND to 42/249 patients or 16.9% in Australia: AUS).
The percentage of NVAF patients treated with antith-
rombotic agents was 75% in the 9 countries on average;
however, the percentage was the lowest (41%) in IND.
Physicians in these countries were asked questions
pertaining to the following points:1)undAwareness and usage of guidelines (European Society
of Cardiology [ESC], American Heart Association [AHA],
Americal Collage of Cardiology [ACC], Japanese Circu-
lation Society [JCS], and others).2) Opinion on the need for an APHRS guideline.
3) Risk stratiﬁcation of AF patients for prevention of
thromboembolism.
4) Antithrombotic agents prescribed for prevention.
5) Satisfaction with current antithrombotic agents.
6) Expectations for new antithrombotic agents.
7) Others.: no. of patients.
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Among the guidelines of the ESC, AHA, ACC, JCS, and
others, the ACCF/AHA/HRS 2011 guidelines [7] were the
most frequently used in 4 countries, namely, AUS (56% of
physicians), KOR (46% of physicians), TWN (52% of phy-
sicians), and SGP (65% of physicians). The ESC 2010
guidelines [6] were the most frequently used in 3 coun-
tries, namely, CHN (30% of physicians), HKG (44% of
physicians), and NZL (59% of physicians). In JPN, 36% of
the physicians used the JCS2008 [5], while in IND, 34% of
the physicians used the ACC/AHA/ESC 2006 [3] and,
interestingly enough, 10% used the JCS2008.
On an average, more than 77% physicians used guide-
lines published by the ACC, AHA, ESC, or HRS, while only
8% of those used the guidelines published from their own
country.
3.2. Opinion on the need for an APHRS guideline
The physicians were asked to rate, on a 6-point scale,
how strongly they felt the need for a guideline from the
APHRS; the average score was 4.3, indicating that many
physicians felt a strong need for a guideline from the
APHRS (Fig. 2). In particular, in CHN, the average score
was 5.0. On the other hand, the average score was 3.4 and
3.7 in NZL and AUS, respectively, indicating that the
physicians in these countries were not as eager to have a
special guidelines from the APHRS. This may be because
approximately 60% of the physicians in these countries use,
and are satisﬁed with, the ACC/AHA or ESC guidelines.
3.3. Reasons for desiring a guideline from the APHRS
The reasons for the physicians’ desire for a guideline
from the APHRS were sought, and the following responses
were obtained: (1) ethnic differences have not been taken
into consideration in the existing guidelines (64%); (2)
guidelines from the Western countries are not necessarilyFig. 2. Opinion on the need for an APHRS guideline.applicable to countries in the Asia-Paciﬁc region (57%);
(3) there are differences in the medical systems between
Western and Asia-Paciﬁc countries (43%); (4) available
drugs are different in different regions (41%); and (5) under-
lying conditions of AF patients in Asia-Paciﬁc countries are
different from those in the United States and Europe (32%).
3.4. Antithrombotic agents prescribed for stroke prevention
With regard to the agents used for stroke prevention in
NVAF patients, oral anticoagulants (OAC) were used in
JPN; as much as 79% of the physicians in JPN used OACs,
with 14% reporting concomitant use of antiplatelet agents
(Fig. 3). This was also the case in AUS and SGP, where 78%
of the physicians used OACs. On the other hand, half the
physicians used antiplatelet agents alone in CHN, TWN,
KOR, and IND, indicating that the superiority of OACs over
antiplatelet agents had not yet been clearly established.
3.5. Antiplatelet agents prescribed for stroke prevention
Physicians using antiplatelet agents for stroke preven-
tion were required to specify the type of the drugs used.
A large majority of the physicians indicated that they used
aspirin, with little difference among countries (Fig. 4).
3.6. Antithrombotic strategy according to CHADS2
Physicians were asked about the content of the antith-
rombotic treatment for patients with CHADS2 scores of 0,
1, and 2, i.e., patients with a history of stroke. It was found
that for patients with a CHADS2 score of 0, most physi-
cians use antiplatelet agents (63%) (Fig. 5). It was also
found that the higher the CHADS2 score, the higher was
the rate of warfarin use, and that a ‘‘no drug’’ policy was
not employed for any patient with a CHADS2 score of 2 or
higher. With respect to a CHADS2 score of 2, there were no
signiﬁcant differences in the content of therapy between
patients with 2 risk factors and those with a history of
stroke as the risk factor.
3.7. Antithrombotic strategy for patients with no risk factors
(CHADS2¼0)
In contrast, when we looked at individual countries, a
large difference was observed (Fig. 6). According to the
JCS2008, a CHADS2 score of 0 is indicative of a low-risk
state and use of warfarin is not essential. Therefore, 46% of
physicians in JPN employed the ‘‘no drug’’ policy for such
patients. On the other hand, in other Asia-Paciﬁc coun-
tries, the large majority of physicians characteristically
used antiplatelet agents. The JCS2008 does not recom-
mend the use of antiplatelet agents because of the
increase in bleeding risk, which was reﬂected in the
remarkably low rate of the use of antiplatelet agents
(16%) in JPN. Further investigation is necessary to deter-
mine whether there are differences in the degree of
recognition of the elevated risk of bleeding among coun-
tries and among ethnic groups.
Fig. 3. Antithrombotic agents prescribed for stroke prevention.
Fig. 4. Antiplatelet agents prescribed for stroke prevention.
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(CHADS2¼1)
For patients with a CHADS2 score of 1, who are also
judged to be low-risk patients, the treatment methods
varied greatly among countries (Fig. 7). In IND, only 2% of
the physicians used warfarin. On the other hand, in most
of the other countries, the rate of warfarin use was as high
as 40%. In JPN, 70% of the physicians used either warfarin
or dabigatran, which was remarkably different from thecase in the other countries. However, in the other coun-
tries, the usage rate of antiplatelet agents alone was also
high for patients with CHADS2¼1; particularly in IND, the
usage rate of antiplatelet agents alone was as high as 70%.
3.9. Antithrombotic strategy for patients with
CHADS2 score 2
For patients with a CHADS2 score of 2, the usage rate
of OACs, including warfarin and dabigatran, was greater
Fig. 5. Antithrombotic strategy according to CHADS2 score.
Fig. 6. Antithrombotic strategy for patients with no risk factors (CHADS2¼0).
S. Ogawa et al. / Journal of Arrhythmia 28 (2012) 41–55 45than 70% in most countries (96% in AUS and SGP and 95%
in HKG), whereas in IND again, 50% of these patients were
treated with antiplatelet agents alone (Fig. 8).
3.10. Optimum international normalized ratio
Generally, the optimum international normalized ratio
(INR) in all the countries was comparable to the recom-
mended level by international guidelines, namely, an INR
of 2 to 3 (Fig. 9). In IND, however, the lower limit was set
at 1.4, a value that is almost ineffective, and the upper
limit was set at 4.1, at which the risk of bleeding is
markedly increased. In JPN, lower levels for the elderlywere set at 1.6 to 2.6 according to the JCS2008, which was
reﬂected in the results. A similar tendency was also
observed in other countries, with the exception of IND.
3.11. Adjustment of the INR according to the age
The subjects were required to respond to the following
question: ‘‘Do you alter the optimum INR setting depending
on the age?’’ Half the physicians responded with ‘‘yes,’’
while the other half responded with ‘‘no’’ (Fig. 10). The
average age at which they altered the optimum INR setting
was 74 years. In IND, physicians altered the setting at 65
years, which is relatively low.
Fig. 7. Antithrombotic strategy for patients with one risk factor (CHADS2¼1).
Fig. 8. Antithrombotic strategy for patients with more than 2 risk factors (CHADS2¼2).
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persistent AF
With regard to this topic, the subjects were asked the
following question: ‘‘Do you prescribe antithrombotic
treatment for paroxysmal AF in the same manner as that
for persistent AF?’’ An average of 68% of the physicians,
with a maximum of 91% in NZL, answered that they
prescribed antithrombotic treatment for paroxysmal AF
as well as for persistent AF (Fig. 11). On the other hand,
this rate was low in TWN, IND, KOR, and CHN. These
results indicate the lack of application of the recommen-
dations of all current guidelines, which are in favor of
using OACs for paroxysmal AF.3.13. OAC during tooth extraction
Most physicians in JPN appeared to be aware of
ﬁndings that tooth extraction can be safely performed
while the patient is still taking warfarin. Surprisingly,
however, in the other countries, the response from most
of the physicians was ‘‘tooth extraction was performed
after discontinuation of warfarin’’ (Fig. 12).
3.14. OAC during endoscopy or surgery
An overall average of 86% of physicians discontinued
OAC administration during endoscopy or surgery, as per
the guidelines; however, in IND, the majority of physicians
Fig. 9. Optimum INR.
Fig. 10. Adjustment of the INR according to the age.
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OAC (Fig. 13).
3.15. OAC during cardioversion for persistent AF and
paroxysmal AF
The overall average rate of warfarin use for cardiover-
sion in cases of paroxysmal AF was lower than that in
cases of persistent AF (59% vs. 73%), with a high positive
response rate for antiplatelet agent use and ‘‘no drug’’policy (Fig. 14). The rate of warfarin use was as low as 20%
to 30% for both persistent and paroxysmal AF patients
in IND.
3.16. Satisfaction rating for warfarin and antiplatelet agents
on a 6-point scale
The results of the satisfaction rating for warfarin and
antiplatelet agents on a 6-point scale are shown on the
left and right sides, respectively (Fig. 15). With regard to
Fig. 11. Antithrombotic treatment for paroxysmal AF vs. persistent AF.
Fig. 12. OAC during tooth extraction.
S. Ogawa et al. / Journal of Arrhythmia 28 (2012) 41–5548the satisfaction rating for warfarin, the highest score of
5.0 was observed for price, followed by the score of 4.6 for
efﬁcacy and evidence. The scores for bleeding risk, drug
interaction, and diet restriction were around 3, clearly
indicating that many physicians were dissatisﬁed with
these factors. On the other hand, in the satisfaction rating
for antiplatelet agents, the mean rating was 3.8, which
was equivalent to that for warfarin; however, the score
was 3.6 for efﬁcacy, clearly lower than the corresponding
score of 4.6 for warfarin.3.17. Awareness level about new anticoagulants
Analysis of the responses to the question related to the
degree of awareness about new anticoagulants in all 9
countries revealed that the awareness level was higher
according to the degree of progression of the drug devel-
opment around the world; 16, 22, 28, and 42% of the
physicians indicated ‘‘I have never heard the name,’’ for
dabigatran, rivaroxaban, apixaban, and edoxaban, respec-
tively (Fig. 16).
Fig. 13. OAC during endoscopy or surgery.
Fig. 14. OAC during cardioversion for persistent AF and paroxysmal AF.
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Dabigatran is already in the market in 6 countries,
namely, AUS, JPN, TWN, HKG, NZL, and SGP and as
expected, the awareness level about dabigatran was high
in these countries (Fig. 17). However, it was somewhat
surprising that as much as 12% of the physicians said
‘‘I have never heard the name,’’ in JPN, where dabigatran
has been on the market since March 2011.3.19. Top 3 reasons for prescribing dabigatran in place of
warfarin
The reasons for prescribing dabigatran in place of
warfarin were queried. Only the overall data for the 9
countries are shown in Fig. 18. Physicians prescribed
dabigatran, not because it can compensate for the dis-
advantages of warfarin, such as drug interaction and diet
restriction, but because of the higher efﬁcacy and lower
S. Ogawa et al. / Journal of Arrhythmia 28 (2012) 41–5550bleeding risk of dabigatran as compared with those of
warfarin. This is evident from the data on the percentages
assigned to the various reasons: efﬁcacy, 77%; bleeding risk,
67%; and ease of administration, 55%. The prescription ofFig. 15. Satisfaction rating for warfarin/antiplatelets.
Fig. 16. Awareness level about new anticoagulants.
Fig. 17. Awareness abdabigatran may have been based on the results of the RE-
LY trial.
3.20. Awareness of CHA2DS2-VASC
The method of risk stratiﬁcation for antithrombotic treat-
ment was queried, and the results are shown in Fig. 19. About
half the physicians in all countries used CHADS2, and the
other half used CHA2DS2-VASC. However, in NZL, 86% of the
physicians used CHA2DS2-VASC, which was proposed by the
ESC2010. This is probably becausemany physicians in NZL, as
stated above, use the ESC guidelines. In JPN, however, 70% of
the physicians used CHADS2.
3.21. Awareness of the concept of Time in Therapeutic
range (TTR)
Overall, 43% of the physicians answered they were aware
of the concept of TTR, while 57% indicated that they were
not (Fig. 20). The concept of TTR is important for stablyout dabigatran.
Fig. 18. Top 3 reasons for prescribing dabigatran in place of warfarin.
Fig. 19. Risk stratiﬁcation based on risk factors.
Fig. 20. Awareness of the concept of TTR (Time in Therapeutic Range).
S. Ogawa et al. / Journal of Arrhythmia 28 (2012) 41–55 51maintaining the preventive effect of warfarin, and awareness
about this concept must be increased among physicians.
3.22. Awareness of the HASBLED (bleeding index)
HASBLED is deﬁned as a risk factor for bleeding by the
ESC2010, and more than half, that is, 57% of the physicians
were aware of HASBLED (Fig. 21). Among 3 countries,
namely, CHN, NZL, and HKG, where the ESC2010 appears to
be the preferred guidelines, the awareness about HASBLED
was low. The awareness levels were also low in JPN and KOR.4. Discussion
Managing AF requires a comprehensive therapeutic
strategy encompassing measures such as the prevention
of complications from cerebral embolisms and heart fail-
ure, in addition to the treatment of the underlying disease
and/or AF itself. Among these, the importance of antic-
oagulant therapy has been widely recognized. During the
past 60 years, only a vitamin K antagonist, warfarin, was
used to prevent cerebral and systemic thromboembolism
for AF patients. However, regular monitoring of blood
Fig. 21. Awareness of the HASBLED (bleeding index).
S. Ogawa et al. / Journal of Arrhythmia 28 (2012) 41–5552coagulation was required to use warfarin safely and
effectively. Thus, there has been a long wait for the
development of much easier-to-use oral anticoagulants.
Under these circumstances, various oral anticoagu-
lants are being developed, and a large-scale comparative
trial with warfarin for AF patients is currently underway.
The direct thrombin inhibitor, dabigatran, in particular,
has attracted much attention because the RE-LY trial
provided evidence that it lowers the risk of stroke/
systemic embolisms without increasing the risk of hemor-
rhage, unlike warfarin [8,9]. Dabigatran has already been
approved in the United States and Canada, as well as in
6 countries in the Asia-Paciﬁc region. It is slated for
approval in several other countries. The approval of new
oral anticoagulants is expected to drastically change the
antithrombotic treatment strategy for AF.
In the meantime, APHRS has launched activities to
formulate regional-oriented guidelines by standardizing
AF treatment in the Asia-Paciﬁc region. This goal was set
on the basis of the ﬁndings of a preliminary survey, which
was conducted by the society’s Practice Guideline Sub-
committee. The survey highlighted the difﬁculty in for-
mulating comprehensive guidelines to cover the entire
arrhythmia ﬁeld in the region due to the huge differences
among the nations with respect to the socio-economic
status, medical-insurance systems, available drugs, and
so on. Standardizing antithrombotic therapy for AF was
chosen as the subcommittee’s ﬁrst mission because the
treatment methods for AF appear to be common through-
out the region.
The scale of the survey was small, but it was the ﬁrst
trial of its type to cover the region. The status of the
treatments unveiled in this survey was more or less as
expected. The survey clariﬁed the gaps among nations in
a number of aspects, which reminds us of the need to
standardize the treatments and at the same time of the
difﬁculty in reaching the goal.4.1. Background of surveyed countries’ physicians and
dependence on guidelines
Although the number of patients for the physicians who
participated varies among countries (from 76 in IND to 571
in TWN), on average, the physicians participating from the 9
countries examined 300 patients per month, and 37 patients
(12%) of this group have NVAF. Since the ratio of patients
with NVAF is not largely divergent among the countries, the
ﬁgure can serve as the average ratio of patients with NVAF.
With regard to whether physicians prescribe antithrombotic
therapy to NVAF patients, 67–87% physicians in 8 countries
answered in the afﬁrmative. The exception was IND, with a
ﬁgure of 41%. The APHRS member representing IND (NM)
commented that doctors in India overestimate bleeding risk
and underestimate stroke risk. While AF is managed, the
need to prevent strokes is counterbalanced by the fact that
warfarin therapy has its limitations. Reports from different
laboratories on the INR have a high co-efﬁcient of variation.
He (NM) added an example that the INR is reported to
be 1.8, while the actual INR may be as high as 2.8. Then,
doctors [in IND] tend to use lower doses of warfarin and
accept lower INR ranges (below 2.0) as a result, and add
aspirin and/or clopidogrel. Neither efﬁcacy nor safety are
addressed adequately in the process.
With regard to the awareness on usage guidelines for
AF, only JPN uses its own guideline. Among the other
countries, the United States and European guidelines
are used extensively. At the same time, there are high
expectations for guidelines speciﬁc to the Asia-Paciﬁc
area, especially in CHN. On the other hand, AUS and
NZL show a lower level of interest. The APHRS member
representing NZL (MS) was of the opinion that most
cardiologists have received at least part of their training
overseas, mainly in the United Kingdom or United States,
and therefore, they may be comfortable following ACC/AHA
or ESC guidelines.
S. Ogawa et al. / Journal of Arrhythmia 28 (2012) 41–55 534.2. Details of antithrombotic therapy
This study on the actual status of antithrombotic
therapy surprisingly revealed that the use of antiplatelet
agents, including aspirin, was high in all the countries
other than JPN (Fig. 3). Many clinical trials [10–12] have
shown that aspirin is less efﬁcacious than warfarin. The
use of antiplatelet agents was excluded from the JCS2008
guideline on the basis of the results of the Japan Atrial
Fibrillation Stroke Trial (JAST) on lone AF [13], where the
primary outcomes (3.1% per year) in the aspirin group
were worse than those in the control group (2.4% per
year) and treatment with aspirin caused a non-signiﬁcant
increase in the risk of major bleeding.
The APHRS member from NZL (MS) explains that
probably, by prescribing aspirin, physicians at least feel
they are doing something for stroke risk, and aspirin is
seen as benign in terms of bleeding risk. There is con-
siderable resistance to the use of warfarin due to the
complexities in monitoring and dosing. Antiplatelet ther-
apy is a half-way step, which does not require monitoring
and provides some stroke relief, especially for low-risk
patients.
The CHADS2 score has been proposed as a tool for the
stratiﬁcation of risk from stroke in patients with AF [14].
Meta-analysis revealed that the net clinical beneﬁt of
warfarin would increase for patients with CHADS2 score
of Z2 [15], thereby justifying the recommendation of
warfarin [3]. However, CHADS2 scores of 0–1, which
account for over half of NVAF patients, have a risk of
1.9–2.8% per year for the development of strokes [14], as
well as a risk for the development of left atrial thrombus
[16]. These issues over the stratiﬁcation of risks were
highlighted for CHADS2 scores of 0 and 1 in the survey
analysis of antithrombotic therapy (Fig. 5), i.e., 63% of
physicians prescribed antiplatelet agents at a CHADS2
score of 0 and 49%, at a CHADS2 score of 1. By country,
JPN’s treatment strategy for low-risk factors showed a
particularly interesting result. The JCS2008 guideline does
not recommend warfarin for a CHADS2 score of 0. In
addition, it excludes the use of aspirin as per the results of
the JAST. Therefore, only 18% of physicians prescribed the
antiplatelet agent alone or as part of ‘‘combination ther-
apy,’’ while 46% followed a ‘‘no drug’’ policy (Fig. 6). This
trend was unique to JPN because most physicians in the
other countries prescribed an antiplatelet agent. This
tendency was obvious at CHADS2 score of 1, wherein
the ratio of the use of antiplatelets in JPN was lower and
that of the use of warfarin was higher than that in the
other countries (Fig. 7).
The ESC2010 [6] guidelines recommend that anticoagu-
lation treatment must deﬁnitively be administered for a
CHADS2 score of Z2, on the basis of the CHA2DS2-VASc
score theory; the guidelines also stress that patients aged
Z75 years should be treated in the same manner as those
with a score of Z2. There is another stratiﬁcation of risk at
low-risk factors that are not included in the above condi-
tions. According to the survey, the number of countries that
use the CHADS2 and CHA2DS2-VASc scoring systems are
almost the same. However, notably, in NZL, where the
number of physicians who use the ESC2010 guidelines arehigh, 86% of physicians use CHA2DS2-VASC. In JPN, 70% of
the physicians use CHADS2 (Fig. 19).
The rate of thromboembolism risk is 1.67% and 0.78%
per year for CHADS2 and CHA2DS2-VASc scores of 0,
respectively, and 4.75% and 2.01%, for with scores of 1
[17]. This indicates that the CHA2DS2-VASc scoring sys-
tem could identify relatively high-risk patients who need
anticoagulation therapy among low-risk patients judged
to be have a CHADS2 score of 0 or 1. In the ESC2010
guidelines, age 65–74 years, females, and vascular disease
are categorized as ‘‘other risk factors’’ and for patients
with 2 risk factors, antithrombotic therapy is recom-
mended. Antithrombotic therapy or aspirin is recom-
mended for patients with 1 risk factor, and no treatment
(or aspirin) for patients with no risk factors. The funda-
mental difference between the JCS2008 and the ECS2010
is that the latter recommends aspirin for low-risk
patients. It is necessary to clarify the net clinical beneﬁt
of prescribing aspirin for these patients.
The trends in JPN and NZL, where dabigatran is
approved, indicate that the higher the risk, the higher
the use of dabigatran, and particularly, in NZL, the rate of
dabigatran use is higher than that of warfarin. These
trends suggest that the relatively high rate of aspirin use
may be related to the resistance to using warfarin (Fig. 8).
Dabigatran has been approved in 6 Asia-Paciﬁc countries to
date, and antiplatelet agents are expected to be gradually
replaced by dabigatran in the future.
4.3. Actual status of warfarin usage
Warfarin is the only available oral anticoagulant agent,
and studies based on meta-analysis have shown that it
helps reduce the risk of strokes in NVAF by 68% [18].
However, when used, several conditions need to be
followed. Despite its several limitations, warfarin was
administered appropriately for patients with a CHADS2
score of Z2, as recommended by the guidelines [3], in all
countries except IND. The appropriate range of INR, in line
with the international standard (2.0–3.0), was also
observed in most countries. In order to prevent the risk
of hemorrhages among the elderly, more than half the
physicians in 7 countries answered that they modiﬁed
INR in line with the patients’ age. Physicians in AUS and
NZL answered ‘‘not modiﬁed,’’ but the maximum value
indicated was less than 2.5 in both countries (Fig. 9).
With regard to the measures taken for patients on
warfarin undergoing tooth extraction, endoscopy, or sur-
gical procedures, the answers obtained from IND and JPN
differed considerably from those obtained from the other
countries. In JPN, 78% of the physicians recommended the
continuation of anticoagulation therapy during tooth
extraction, whereas most physicians in other countries
stop the therapy. This is concerning because the patients
are at a risk of embolism while the anticoagulation
therapy is stopped. Serious thromboembolism occurs in
about 1% of patients with AF after the discontinuation of
warfarin [19,20]. Randomized controlled studies and obser-
vational studies have reported that tooth extraction can be
safely performed on patients receiving antithrombotic drugs
[21,22]. This was found as a common practice in JPN [5].
S. Ogawa et al. / Journal of Arrhythmia 28 (2012) 41–5554Until recently, dentists in JPN were also concerned
about continuing warfarin administration for patients
undergoing tooth extractions. However, the Japanese
Association for Dental Science together with the Japanese
Circulation Society have together provided sufﬁcient evi-
dence to eliminate this concern and have published
relevant guidelines. Therefore, currently, tooth extrac-
tions in JPN are being conducted safely while continuing
antithrombotic therapy.4.4. Paroxysmal AF vs. persistent AF
It seems to be well-accepted in most countries that
paroxysmal AF and persistent AF pose the same risk of
thromboembolism. In the 9 countries, an average of 68%
of physicians answered that they administered antith-
rombotic therapy for both paroxysmal and persistent AF.
On the other hand, the therapy during deﬁbrillation
varied, even among physicians who answered that there
were the same risk factors with paroxysmal/persistent AF.
The percentage of warfarin use was lower in the case of
paroxysmal AF (59% versus 73%). However, in AUS, NZL,
and SGP, 90–100% of the physicians prescribed antic-
oagulation therapy, including direct thrombin inhibitor
for both paroxysmal and persistent AF, followed by
JPN and HKG. On this point, IND again showed a large
difference with respect to prescribing anticoagulation
therapy; the percentages for paroxysmal and persistent
AF were 38% and 36%, respectively.
In the other countries of CHN, KOR, IND, and TWN,
32–38% of physicians administered only antiplatelet agents
during deﬁbrillation for both paroxysmal and persistent AF.
Although the evidence indicated that paroxysmal AF and
persistent AF should be given equal importance [3,23], the
survey revealed differences in the situation in the Asia-
Paciﬁc region. It is necessary to conduct a ﬁeld survey on the
rate of embolism during deﬁbrillation.4.5. Expectations for new developments in oral
anticoagulant agents
Dabigatran can be administered in ﬁxed doses, with-
out the need for continuous monitoring. It also takes a
shorter period than warfarin to conﬁrm efﬁcacy, and its
disposition and pharmacodynamic action are predictable.
There are no food restrictions during the intake of this
drug, and cross-interaction with other agents is minimal.
As indicated by the RE-LY trial [8,9], the use of dabigatran
does not result in increases in the rates of major bleeding
phenomena, while stroke and systemic embolism rates
were lowered or remained unchanged. These points
justify the positive promotion of dabigatran for AF ther-
apy. According to the physicians participating in this
survey, the characteristics of dabigatran, namely, efﬁcacy,
hemorrhage risk, and ease of dosage determination,
render it a suitable replacement for warfarin. Further,
awareness about factor Xa inhibitors, which are currently
under development, was high, with physicians having big
expectations for it.4.6. Limitations of the study
The possibility that the results in each country were
affected by the backgrounds of the physicians who parti-
cipated in the Web survey is a major limitation of this
study. When screening respondents to the questionnaire
in this survey, physicians who (1) examined 50 or fewer
patients with cardiovascular disease, (2) examined no
patients with atrial ﬁbrillation, or (3) had not adminis-
tered antithrombotic therapy for NVAF patients during
the last 1 month were excluded. However, even if these
conditions were fulﬁlled, the experience and knowledge
of the respondent physicians would have been uneven,
because only 50 physicians were surveyed in each coun-
try. Therefore, the responses should be interpreted cau-
tiously. For example, the number of beds in the hospitals
in which the physicians worked was also uneven, and in
IND, 44% of the physicians worked in small-scale hospitals
with 9 beds or less. This may have caused the large
differences in the view on antithrombotic therapy between
physicians in IND and other countries.
Although the survey was rather small in scale and
the results raised a number of concerns, it revealed that
appropriate antithrombotic treatment was not always
administered to NVAF patients in some countries. For
the implementation of corrective measures, it will be
necessary to determine the common features among
and differences between the participating countries with
respect to the different aspects of therapy. It is imperative
to formulate an APHRS guideline for use in Asia-Paciﬁc
countries. We hope all the physicians who contribute to
AF therapy in each country are made aware of the current
situation through these survey results. We truly hope to
gain momentum toward formulating guidelines.
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